Overview
- 185 inspections across 157 sites are on record.
- 111 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-06-12.
At a glance
Inspections
185
Sites
157
Observations
111
Career since
May 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Daniel B. Landi, M.D. | 12 Jun 2026 | Biologics | |
| Kathryn J. Lucas, M.D. | 21 May 2026 | Human Drugs | |
| Prof. Tomasz Wrobel MD, PhD | 28 Apr 2026 | Human Drugs | |
| Prof. Maciej Harat, MD, PhD | 17 Apr 2026 | Medical Devices & Rad Health | |
| Regeneron Pharmaceuticals, Inc. | 27 Mar 2026 | Human Drugs |
Sites inspected
Daniel B. Landi, M.D.Durham, United States1 insp.
Kathryn J. Lucas, M.D.Morehead City, United States1 insp.
Prof. Tomasz Wrobel MD, PhDWroclaw, Poland1 insp.
Prof. Maciej Harat, MD, PhDBydgoszcz, Poland1 insp.
Regeneron Pharmaceuticals, Inc.Armonk, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Michelle D Haamid4 shared
Nigel L Hirth3 shared
Anthony J Grace2 shared
Erin M Mcdowell2 shared
Mark J Seaton2 shared
Zhou Chen2 shared
Heather M Wheeler2 shared
Amanda M Szucsik1 shared
Mei Ou1 shared
Jeanne J Thai1 shared
Full investigator report
Get the verbatim findings behind Betsy C Galliher's 111 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site